##1: The Core of Leukemia Relapse: Hidden Link Between Stemness and Repetitive DNA The greatest obstacle to treating acute myeloid leukemia (AML) is the presence of leukemia stem cells (LSCs) that survive intensive chemotherapy and drive relapse. While many studies have focused on mutations in protein‑coding genes, these have been insufficient to fully explain the unique mechanisms that maintain stemness in LSCs. This study found the answer in repetitive DNA sequences known as transposable elements (TEs), which constitute a substantial portion of the genome yet whose functions have remained enigmatic.

##2: Reconfiguration of Transposable Elements Revealed by Chromatin Accessibility Mapping The research team generated high‑resolution chromatin accessibility maps for normal blood cells and a range of AML patient samples. Analysis identified specific TE subfamilies whose chromatin became selectively open or closed only in leukemia stem cells. This indicates that previously dormant transposable elements are epigenetically reawakened in LSCs, functioning as regulatory switches that activate gene networks sustaining stemness.

##3: Precise Clinical Prognostication: Diagnostic Value of TE Signatures The chromatin accessibility patterns of these transposable elements provided not only a biological insight but also strong clinical predictive power. Patients harboring a specific TE signature exhibited markedly lower response rates to standard therapy and a statistically significant higher risk of relapse. Thus, assessing TE status alone could precisely diagnose prognosis and enable early identification of high‑risk patients, heralding a novel biomarker.

##4: A New Horizon for Epigenetic Targeted Therapy These findings propose a novel therapeutic strategy capable of fundamentally disrupting the stemness of leukemia stem cells. While correcting the underlying genetic mutations is challenging, epigenetic drugs that modulate the chromatin state of TEs can block the survival engine of LSCs. Integration of TE‑based precision diagnostics with targeted therapy could dramatically reduce AML relapse rates and markedly improve the completeness of personalized treatment.